Instructions to Contributors

Dear Contributor:

Enclosed in this document please find the page proofs, copyright transfer agreement (CTA), and offprint order form for your article in the Seminars in Neurology, Volume 33, Number 4, 2013. Please print this document and complete and return the CTA and offprint order form, along with corrected proofs, within 72 hours.

1) Please read proofs carefully for **typographical** and **factual** errors only; mark corrections in the margins of the proofs in blue or black pen; please be sure to write as clearly as possible so no errors are introduced into your article. **Answer (on the proofs) all author queries marked in the margins of the proofs.** Check references for accuracy. **Please check on the bottom of the 1st page of your article that your titles and affiliations are correct.** Avoid elective changes, because these are costly and time consuming and will be made at the publisher’s discretion.

2) Please pay particular attention to the proper placement of figures, tables, and legends. Please provide copies of any formal letters of permission that you have obtained.

3) **Please return the corrected proofs, signed copyright transfer agreement, and your offprint order form.**

4) As a contributor to this journal you will receive a complimentary PDF file of the article after publication.

- If you wish to order offprints, **please circle the quantity required** (left column) and **the number of pages in your article.** If you wish to order copies of the journal please enter the number of copies on the indicated line.

- If you do not want to order offprints or journals simply put a slash through the form, **but please return the form.**

Please return all materials within 72 hours. E-mail is the easiest way to ensure your corrections are received in a timely manner. You may also return materials via fax or overnight mail to:

Teresa Exley, Production Editor
Absolute Service, Inc.
8600 LaSalle Road, The Oxford Building,
Suite 602
Towson, Maryland 21286
Phone: 410-830-6022
Fax: 410-830-4099
Email: teresa.exley@absoluteserv.com

Please do not return your materials to the editor or the typesetter.

*Please note:* Due to a tight schedule, if the publisher does not receive the return of your article proofs within 7 days of the date the e-mail was sent to you, the publisher reserves the right to proceed with publication without author changes. Such proofs will be proofread by the editor and the publisher.

Thank you for your contribution to this journal.
Thieme Medical Publishers, Inc. (the “Publisher”) will be pleased to publish your article (the “Work”) entitled ___________________________ in the Seminars in Neurology, Volume 33, Number 4, 2013.

The undersigned Author(s) hereby assigns to the Publisher all rights to the Work of any kind, including those rights protected by the United States Copyright laws.

The Author(s) will be given permission by the Publisher, upon written request, to use all or part of the Work for scholarly or academic purposes, provided lawful copyright notice is given.

If the Work, subsequent to publication, cannot be reproduced and delivered to the Author(s) by the publisher within 60 days of a written request, the Author(s) is given permission to reprint the Work without further request.

The Publisher may grant third parties permission to reproduce all or part of the Work. The Author(s) will be notified as a matter of courtesy, not as a matter of contract. Lawful notice of copyright always will be given.

Check appropriate box below and affix signature.

[ ] I Sign for and accept responsibility for transferring copyright of this article to Thieme Medical Publishers, Inc. on behalf of any and all authors.

**Author’s full name, degrees, professional title, affiliation, and complete address:**

Author’s printed name, degrees ____________________ Professional title ____________________

______________________________

______________________________

Complete professional address

Author’s signature ____________________ Date ____________________

[ ] I prepared this article as part of my official duties as an employee of the United States Federal Government. Therefore, I am unable to transfer rights to Thieme Medical Publishers, Inc.

Author’s signature ____________________ Date ____________________
Order Form for Offprints and additional copies of the Seminars in Neurology
(Effective January 2013)

Please circle the cost of the quantity/page count you require (orders must be in increments of 100)

<table>
<thead>
<tr>
<th>Quantity</th>
<th>1 to 4</th>
<th>5 to 8</th>
<th>9 to 12</th>
<th>13 to 16</th>
<th>17 to 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>$298</td>
<td>$497</td>
<td>$746</td>
<td>$968</td>
<td>$1,158</td>
</tr>
<tr>
<td>200</td>
<td>$397</td>
<td>$646</td>
<td>$970</td>
<td>$1,258</td>
<td>$1,495</td>
</tr>
<tr>
<td>300</td>
<td>$496</td>
<td>$798</td>
<td>$1,198</td>
<td>$1,568</td>
<td>$1,869</td>
</tr>
<tr>
<td>400</td>
<td>$549</td>
<td>$886</td>
<td>$1,330</td>
<td>$1,735</td>
<td>$2,075</td>
</tr>
<tr>
<td>500</td>
<td>$598</td>
<td>$966</td>
<td>$1,450</td>
<td>$1,886</td>
<td>$2,262</td>
</tr>
<tr>
<td>1000</td>
<td>$1,076</td>
<td>$1,739</td>
<td>$2,610</td>
<td>$3,385</td>
<td>$3,995</td>
</tr>
</tbody>
</table>

Volume/Issue #: ___________________________ Page Range (of your article): ___________________________

Article Title: ___________________________

MC/Visa/AmEx No: ___________________________ Exp. Date: ________________

Signature: ___________________________

Name: ___________________________

Address: ___________________________

City/State/Zip/Country: ___________________________

Corresponding author will receive a complimentary PDF of the article after publication.

Number of additional copies of the journal, at the discounted rate of $25.00 each: ___________________________

Notes
1. The above costs are valid only for orders received before publication of the issue. **Reprints ordered after printing will be substantially more expensive.**

2. A shipping charge will be added to the above costs.

3. Reprints are printed on the same coated paper as the journal and saddle-stitched.

4. For larger quantities or late orders, please contact reprints department:  
   Phone: +1(212) 584-4662  
   Fax: +1(212) 947-1112  
   E-mail: reprints@thieme.com
The Genetics of Dementia

Janice L. Farlow¹  Tatiana Foroud, PhD¹

¹Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana

Abstract

Over the past decade, there has been a dramatic evolution of genetic methodologies that can be used to identify genes contributing to disease. Initially, the focus was primarily on classical linkage analysis; more recently, genomewide association studies, and high-throughput whole genome and whole exome sequencing have provided efficient approaches to detect common and rare variation contributing to disease risk. Application of these methodologies to dementias has led to the nomination of dozens of causative and susceptibility genes, solidifying the recognition that genetic factors are important contributors to the disease processes. In this review, the authors focus on current knowledge of the genetics of Alzheimer’s disease and frontotemporal lobar degeneration. A working understanding of the genes relevant to common dementias will become increasingly critical, as options for genetic testing and eventually genespecific therapeutics are developed.

Keywords

► genetic risk factors
► dementia
► Alzheimer’s disease
► frontotemporal lobar degeneration

Overview of Modern Genetic Technologies

The past few decades have seen exponential advances in the ability to identify genes contributing to disease. Beginning with the identification of microsatellite markers and then single nucleotide polymorphisms (SNPs) in the early 1990s, researchers were able to interrogate the genome to detect genes causing Mendelian disorders. Linkage analysis was the most common use of these markers and sought to identify chromosomal regions shared by affected members within a family. It was hypothesized that a gene that caused the disease lay within these shared chromosomal regions. The result of linkage analysis was a rapid identification of the genetic cause for many Mendelian disorders. This in turn has provided key insights into disease pathogenesis and in some cases has led to novel therapeutics.

Over the past decade, advancing genetic technologies have allowed millions of SNPs to be efficiently interrogated using genotyping arrays. These arrays include primarily common variation and have allowed scientists to explore new hypotheses about the role of genetics in human disease. For example, studies can now be designed to identify genetic factors that increase or decrease the risk of disease. The most common approach that has been used is a genomewide association study (GWAS), which compares a sample of cases with disease to controls who do not have the disease. Because many genetic risk factors have modest individual effect on disease risk, large samples of cases and controls are needed to obtain robust, reproducible associations. More recently, meta-analysis has been widely used to combine results from multiple studies. This has resulted in studies using data from thousands of cases and controls to identify SNPs that are associated with disease risk. A GWAS is based on the premise of linkage disequilibrium, meaning that many SNPs are tested and used as proxies for the entire genome. Thus, analyses can determine that a SNP is associated with disease risk, but cannot confirm that this particular SNP functionally contributes to disease risk.

In the past few years, technology has further advanced to allow sequencing of DNA to be cost effective on a large scale. Rather than limiting sequencing to a gene or a small region of a chromosome, it is now possible to sequence the entire genome (whole genome sequencing) or only the gene-coding regions, the gene exons (whole exome sequencing). The ability to perform such extensive DNA sequencing has allowed researchers to examine the role of rare variation in disease. For example, whole exome sequencing within a family or across many families can be used to identify genes in which rare variants are found at greater frequency among the affected individuals as compared with control subjects.
The Genetics of Alzheimer’s Disease

Alzheimer’s disease is the most common neurodegenerative disorder among the elderly, as well as the most common cause of dementia overall. The key neuropathologic findings in AD are amyloid plaques composed of β-amyloid (Aβ) and neurofibrillary tangles consisting of the tau protein. Alzheimer’s disease is likely caused by a combination of genetic and environmental factors. Alzheimer’s disease is typically categorized into early onset (EOAD; onset < 60 years) and late-onset (onset ≥ 60 years). Early-onset Alzheimer’s disease makes up less than 5% of cases, but because a subset of families has a clear pattern of Mendelian inheritance, mutations have been identified in several causative genes. The identification of these genes has significantly advanced the understanding of the biological underpinnings of all AD cases.

Early-Onset Alzheimer’s Disease

Researchers observed that among families with EOAD, a significant number displayed autosomal dominant inheritance. This allowed linkage analysis to be successfully employed to identify three causative genes (APP, PSEN1, and PSEN2).

APP was the first EOAD gene to be identified.\(^1,2\) It is located on chromosome 21 and encodes the β-amyloid precursor protein. The β-amyloid precursor protein is a neuronal protein that is sequentially cleaved by two specific proteases (β-secretase and γ-secretase) to release Aβ. Even before APP was identified, biochemical analysis had identified cerebral Aβ deposits in the brains of patients with AD. In addition, it had been found that patients with Down’s syndrome were more likely to develop AD; therefore, it was predicted that a gene on chromosome 21 would function to produce Aβ and would cause AD when mutated.\(^3\)

Mutations in APP are found in less than a quarter of EOAD patients. A variety of different mutations have been found in APP including point mutations, gene duplications, and gene deletions. All APP mutations reported to be pathogenic are located at secretase sites or inside the sequence for the resulting Aβ peptide, in or near exons 16 and 17 (\(\text{Fig. 1}\)).\(^4\)

The majority of EOAD mutations are found in the presenilin 1 (PSEN1) gene, located on chromosome 14 and discovered a few years after APP.\(^5\) There have been 185 different mutations found in this gene alone, most clustering in the transmembrane portion of the protein. Sequence homology with PSEN1 prompted the relatively rapid identification of the presenilin 2 (PSEN2) gene on chromosome 1.\(^6,7\) Mutations in this gene are quite rare and were initially due to a founder mutation among individuals of Volga-German ancestry. Mutations in PSEN2 have now been found in individuals of other ancestry as well.\(^8-10\) Of those that have been reported as pathogenic mutations, the distribution within resultant protein domains is similar to that of PSEN1. Together, presenilin 1 (PSEN1) and presenilin 2 (PSEN2) serve as critical catalytic components of the γ-secretase.\(^11\)

Over 200 different mutations have been identified in these three EOAD genes, and most are fully penetrant (\(\text{\(\text{Table 1}\}}\); consult the Alzheimer Disease and Frontotemporal Dementia Mutation database, http://www.molegen.ua.ac.be/ADMutations, for updated information).\(^12\) Disease-causing mutations in these three genes all lead to an increase in extracellular Aβ or a relative overabundance of the Aβ\(_{42}\) species, which is thought to increase Aβ aggregation and amyloid fibril formation.\(^13\) The discovery of APP, PSEN1, and PSEN2 contributed to the amyloid hypothesis, which posits that amyloid plays a critical role in AD pathology.

Late-Onset Alzheimer Disease

Although most LOAD cases do not have a clear heritable etiology, genetic factors still play an important role in disease risk. The lifetime risk of developing AD is \(\sim 10\%\), and is twice that for individuals having an affected first-degree relative with AD.\(^14\) Studies have estimated that the genetic
contribution to LOAD susceptibility (i.e., heritability) is as high as 80%.15 Of note, no single gene has been identified that has a causative effect on disease risk in LOAD, which would be analogous to the role of APP, PSEN1, or PSEN2 in EOAD.

The apolipoprotein E gene (APOE) was the first gene discovered as a risk factor for LOAD, and it remains the identified locus that confers the greatest susceptibility to the disease. APOE is a well-known gene involved in lipid metabolism, and it is thought to be important in Aβ clearance, as well. There are three isoforms of APOE (ε2, ε3, ε4) that differ by a single amino acid substitution. It has been shown that this minor difference leads to different levels of clearance of Aβ, with the ε4 allele of APOE (APOE4) significantly decreasing the speed of clearance at the blood–brain barrier.16

The ε4 allele of APOE (APOE4) increases the risk of AD with reported odds ratios ranging from 4 to 15.17 The effect of APOE4 is consistently present across populations and ethnicities.18–20 The APOE4 effect is additive, with those having two APOE4 alleles having a 15-fold greater risk of AD as compared with the 4-times increased risk for those carrying a single copy of the risk allele.21 Meanwhile, the ε2 allele (APOE2) decreases the risk of AD by approximately a quarter, and is considered a protective allele.22 The ε3 allele of APOE (APOE3), the most common of the 3 APOE isoforms, has not been shown to have a detrimental or protective effect. Importantly, the APOE2 and APOE4 alleles modify the risk of AD, but neither is causative (i.e., sufficient to cause or protect against AD alone).

Other than APOE, almost 50 additional genetic risk factors have now been linked to AD. Varying levels of support exist for each gene. Nine genes have been labeled as established risk factors for AD, based on genome-wide significance (p value \( \leq 5 \times 10^{-8} \)) in meta-analyses and replication in multiple studies.22 Much work remains to characterize exact variants in or near these susceptibility genes; however, the genes have been linked to the metabolism of Aβ and synaptic function (APOE, BIN1, CD33, CLU, CR1, PICALM), the immune system and inflammation (ABCA7, CD33, CLU, CR1, MS4A), and lipid metabolism (ABCA7, APOE, BIN1, CLU, PICALM). These susceptibility genes, with the exception of APOE, all confer a relatively small risk for AD, with odds ratios of 0.85 to 1.2 (Table 2).23,24

The proportion of LOAD cases that could be prevented if these nine (GWAS-identified) genetic risk factors were eliminated, referred to as the cumulative population attributable risk, is estimated to be as high as 35%.25 Studies are actively underway to identify additional disease-related associations in LOAD.

### Genetics of Frontotemporal Lobar Degeneration

Frontotemporal lobar degeneration (FTLD) is a term that describes the neuropathology underlying several different clinical syndromes, all characterized by progressive damage to the frontal and/or temporal lobes of the brain. As a result, behavior and language are progressively impaired in individuals affected with FTLD. Frontotemporal lobar degeneration

### Table 1 Mendelian genes causing familial early-onset Alzheimer’s disease (EOAD)

<table>
<thead>
<tr>
<th>Gene</th>
<th>Protein</th>
<th>Chromosome location</th>
<th>Mutation frequency in EOAD patients</th>
<th>Types of mutations reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>APP</td>
<td>B-amyloid precursor protein</td>
<td>21q21.2</td>
<td>6–26%</td>
<td>Missense, duplications, deletions</td>
</tr>
<tr>
<td>PSEN1</td>
<td>Presenilin 1</td>
<td>14q24.3</td>
<td>28–61%</td>
<td>Missense, deletions, insertions</td>
</tr>
<tr>
<td>PSEN2</td>
<td>Presenilin 2</td>
<td>1q31–42</td>
<td>Rare</td>
<td>Missense</td>
</tr>
</tbody>
</table>

*Mutation frequencies reported by Cohn-Hokke et al.*31

### Table 2 Established risk loci for late-onset Alzheimer’s disease

<table>
<thead>
<tr>
<th>Gene</th>
<th>Protein</th>
<th>Chromosome location</th>
<th>Effect size / Odds ratio (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCA7</td>
<td>ATP-binding cassette, subfamily A, member 7</td>
<td>19p13.3</td>
<td>1.23 (1.18–1.28)</td>
</tr>
<tr>
<td>APOE</td>
<td>Apolipoprotein E</td>
<td>19q13.32</td>
<td>ε3ε4 genotype 3.2 (2.8–3.8) ε4ε4 genotype 14.9 (10.8–20.6)</td>
</tr>
<tr>
<td>BIN1</td>
<td>Bridging integrator 1</td>
<td>2q14.3</td>
<td>1.17 (1.13–1.20)</td>
</tr>
<tr>
<td>CD2AP</td>
<td>CD2-associated protein</td>
<td>6p12.3</td>
<td>1.12 (1.08–1.16)</td>
</tr>
<tr>
<td>CD33</td>
<td>CD33 molecule</td>
<td>19q13.41</td>
<td>0.85 (0.86–0.92)</td>
</tr>
<tr>
<td>CLU</td>
<td>Clusterin</td>
<td>8p21.1</td>
<td>0.89 (0.86–0.91)</td>
</tr>
<tr>
<td>CR1</td>
<td>Complement component receptor 1</td>
<td>1q22.2</td>
<td>1.19 (1.09–1.30)</td>
</tr>
<tr>
<td>MS4A4E, MS4A6A</td>
<td>Membrane-spanning 4-domains, subfamily A, member 4E and 6A</td>
<td>11q12.2</td>
<td>0.90 (0.88–0.93)</td>
</tr>
<tr>
<td>PICALM</td>
<td>Phosphatidylinositol binding clathrin assembly protein</td>
<td>11q14.2</td>
<td>0.88 (0.86–0.91)</td>
</tr>
</tbody>
</table>

*Effect sizes calculated from Alzheimer’s Disease Genomics Initiative*.
typically presents at an earlier age than AD (≈ 45–65 years of age) and represents the second most common cause of dementia in those under 65 years of age. Almost half of individuals with FTLD have other affected family members, and an autosomal dominant mode of transmission can be identified in ~10% of patients. 

Six unrelated genes with over 150 reported mutations have been implicated in FTLD (∼Table 3; Alzheimer Disease and Frontotemporal Dementia Mutation database). Mutations in three genes (C9orf72, GRN, MAPT) are the most common, with rarer causative mutations found in the remaining three genes (CHMP2B, TARDBP, VCP). Individuals with mutations in C9orf72, GRN, or MAPT often present with the most common frontotemporal dementia clinical syndrome, the behavioral variant (bvFTD). Together, mutations in these three genes account for at least 17% of familial FTLD. Although there are strong correlations between the mutated gene and the patient’s neuropathology, there is typically not a clear association between the implicated gene and clinical phenotype. 

Microtubule-associated protein tau (MAPT), located on chromosome 17, is involved in microtubule assembly and maintenance, and has been implicated in FTLD, AD, and other neurologic diseases. Over 40 mutations have been reported in the gene since its discovery in 1998, mostly in exons 9–13 (∼Fig. 2). Mutations result in a change in the ratio of the three amino acid (3R) and four amino acid (4R) isoforms and are believed to increase the tendency of tau to form neurotoxic aggregates. Mutations in MAPT are found in ~9 to 21% of FTD patients.

Some FTLD families demonstrated genetic linkage to chromosome 17, but surprisingly no mutations in MAPT could be found. It was later discovered that many of these families had mutations in progranulin (GRN), located only 6 Mb from MAPT. Over 60 disease-producing mutations have been reported in GRN. Most result in a premature stop codon and the resulting mRNA is degraded through nonsense-mediated decay resulting in haplo insufficiency. Of note, there is substantial clinical variability in patients carrying a GRN mutation. Mutations have been reported among individuals diagnosed clinically with language variants and bvFTD, AD, corticobasal degeneration, and mild cognitive impairment. The age of onset has varied widely, even within families. GRN mutations are found in ~4 to 23% of all FTLD patients.

Recently, expansions of a GGGGCC hexanucleotide repeat in the noncoding portion (first intron) of C9orf72 on chromosome 9 have been associated with both FTLD and amyotrophic lateral sclerosis (ALS). The repeat number, typically less than 25 units in normal individuals, is expanded to greater than 60 units in FTLD. The expanded number of repeats results in the loss of one alternatively spliced transcript. However, the function of this lost transcript is not yet known. Estimations for the percentage of familial ALS and familial FTLD cases in North American populations attributable to the C9orf72 mutation range from 23.5 to 36.2% and 6.3 to 19.1%, respectively. The C9orf72 mutation appears to be more common among northern European populations.

Mutations in the other three genes, chromatin modifying 2B (CHMP2B), valosin-containing protein 1 (VCP-1) and TAR-DNA-binding protein 43 encoding gene (TARBP), are rare causes of FTD, found in only a few families each. The phenotype in each is quite different and may also be associated with non-FTD phenotypes. For example, some VCP-1 mutations are associated with Paget’s disease of the bone.

There has only been one systematic FTLD GWAS, which reported TMEM106B on chromosome 7 as a potential susceptibility gene for FTLD cases with TAR-DNA-binding protein inclusions. The identified SNPs were associated with increased TMEM106B expression, but the mechanism of upregulation and the development of FTLD has not been established.

Genetic Counseling and Testing

Definitive diagnoses for AD and FTD can only be made at autopsy, but genetics may be used to increase diagnostic and prognostic accuracy. With the current limitations regarding disease-modifying therapies for neurodegenerative diseases and the complex ethical considerations involved in genetic testing, clinicians must carefully consider the appropriateness of genetic analyses for patients. Because both positive and negative findings have significant implications for the patient and family, thorough genetic counseling is advised before and after any genetic testing is performed. For genetic tests that are not commercially available, the tests may be available in the academic research setting. As more is learned about the genetics of AD and FTLD, commercial availability of genetic testing, and even direct to consumer testing, will

Table 3 Mendelian genes causing frontotemporal lobar degeneration (FTLD)

<table>
<thead>
<tr>
<th>Gene</th>
<th>Protein</th>
<th>Location</th>
<th>Mutation frequency in FTLD patients</th>
<th>Types of mutations reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAPT</td>
<td>Microtubule-associated protein tau</td>
<td>17q21.1</td>
<td>9–21%</td>
<td>Missense, deletions</td>
</tr>
<tr>
<td>GRN</td>
<td>Progranulin</td>
<td>17q21.31</td>
<td>4–23%</td>
<td>Missense, deletions, insertions</td>
</tr>
<tr>
<td>C9orf72</td>
<td>Chromosome 9 open reading frame 72</td>
<td>9p21</td>
<td>18–30%</td>
<td>Hexanucleotide repeat expansion</td>
</tr>
<tr>
<td>TARDBP</td>
<td>TAR DNA binding protein</td>
<td>1p36.22</td>
<td>Rare</td>
<td>Missense</td>
</tr>
<tr>
<td>VCP</td>
<td>Valosin-containing protein</td>
<td>9p13.3</td>
<td>Rare</td>
<td>Missense</td>
</tr>
<tr>
<td>CHMP2B</td>
<td>Charged multivesicular body protein 2B</td>
<td>3p11.2</td>
<td>Rare</td>
<td>Missense</td>
</tr>
</tbody>
</table>

*Mutation frequencies calculated by Cohn-Hokke PE et al.31*
likely increase. As treatments are developed, testing options will likely expand further. Clinicians will need to be familiar with these options in an effort to counsel patients.

At present, routine DNA testing in AD is advisable only for EOAD, if the presenting affected individual is a young or middle-aged adult (onset < 60 years). Testing for mutations in PSEN 1, PSEN 2, and APP is currently commercially available. APOE genotyping is also available, and there are ongoing studies assessing the advantages and disadvantages of APOE genotyping. Most groups do not currently recommend the test for predictive risk assessment. 

With the heterogeneity of FTLD, the recommendations for genetic testing in symptomatic patients and their families are more complex. Considerations include the type of FTLD, the extent of family history, and the availability and findings of autopsy tissue from an affected family member. Genetic testing is available for MAPT, GRN, VCP, and C9orf72 in the United States. A full algorithm for when genetic testing should be recommended has been previously reported.

Conclusion and Outlook

Although much has been discovered about the genetics of dementia, the genetic contribution to the vast majority of sporadic and some Mendelian cases of dementia has not yet been elucidated. Modern genetic technologies have helped identify causative and risk loci, but much work remains to characterize the biological mechanisms of these genes and the disease-producing mutations. As additional genetic loci are recognized and characterized, correlations between genotypes and phenotypes will become better understood. Phenotypes will not only include presenting symptoms, but also biomarkers such as structural and functional imaging and composition of the cerebrospinal fluid. Methodologies for screening, diagnosis, and prognosis will improve as additional genes and mutations are identified and correlated with increasingly specific phenotypes. Most importantly, advancing knowledge of underlying genetic factors in neurodegenerative dementias will inform the pursuit of preventative and disease-modifying therapies.

Acknowledgments

This publication was made possible by Grant Number TL1 TR000162 (A. Shekhar, PI) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award, as well as the National Cell Repository for Alzheimer’s Disease, which receives government support under the cooperative agreement grant U24 AG21886.

References


35 Galimberti D, Scarpini E. Genetics of frontotemporal lobar degeneration. Front Neurol 2012;3:52


Author Query Form (SIN/00885)

Special Instructions: Author please write responses to queries directly on proofs and then return back.

Q1: AU: Please provide degree.
Q2: AU: Is “interrogate” the right word here?